Please assess the completion status of the following clinical trial:

Trial Title: A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Genotype 3 HCV~* HCV RNA ≥10000 IU (International Unit)/mL~* Compensated Liver Cirrhosis~* BMI 18-40 kg/m2~* Previously treated for HCV or never treated for HCV~Exclusion Criteria:~* Infection with HCV other than Genotype 3. Mixed infection of any genotype~* Evidence of decompensated liver disease~* Previous exposure to NS5A inhibitors~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) (Type: EXPERIMENTAL): Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).